The Potent and Selective Beta3-adrenoceptor Agonist Mirabegron Improves Patient-reported Outcomes in Overactive Bladder–Results from Two Phase III Studies

Nitti V1, Herschorn S2, Auerbach S3, Khullar V4, Amarenco G5, Blauwet M B6, Boerrigter P7, Hakimi Z8, Siddiqui E9, Martin N10

Abstract Category

Detrusor Overactivity

Abstract 68
LUTS Etiology and Treatment
Scientific Podium Poster Session 7
Wednesday 17th October 2012
14:55 - 15:00
1. NYU Langone Medical Center, Department of Urology, New York, NY, USA, 2. University of Toronto, Division of Urology, Toronto, Canada, 3. Hoag Memorial Presbyterian Hospital, Newport Beach, CA, USA, 4. St Mary’s Hospital, Imperial College, Urogynaecology Department, London, UK, 5. Department of Neurologic Rehabilitation, Urodynamic and Neurophysiology Laboratory, Hôpital Rothschild, Assistance Publique-Hôpitaux de Paris, Paris, France, 6. Astellas Pharma Global Development, Inc., Biostatistics, Deerfield, IL, USA, 7. Astellas Pharma Global Development EU, Leiderdorp, The Netherlands, 8. Astellas Pharma Europe, Leiderdorp, The Netherlands, 9. Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 10. Astellas Scientific and Medical Affairs, Inc. Deerfield, IL, USA
Presenter
S

Sender Herschorn

Links

Abstract